41 results
Keyword Adapalene Remove keyword
-
List item
Referral: Retinoid-containing medicinal products
acitretin, adapalene, alitretinoin, bexarotene, isotretinoin, tretinoin, tazarotene, associated names: Targretin, Panretin, Article 31 referrals
Status: European Commission final decision, opinion/position date: 22/03/2018, EC decision date: 21/06/2018, Last updated: 02/07/2018active substances acitretin, adapalene, alitretinoin, bexarotene … • For topical retinoids (adapalene, alitretinoin, isotretinoin … topically applied retinoids (adapalene, alitretinoin, isotretinoin … -
List item
Referral: Basiron AC and associated names
benzoyl peroxide, Article 13 referrals
Status: European Commission final decision, opinion/position date: 28/03/2019, EC decision date: 04/07/2019, Last updated: 19/07/2019Epiduo (benzoyl peroxide and adapalene), containing the gelling agent … -
List item
Press release: Updated measures for pregnancy prevention during retinoid use
CHMP, Last updated: 23/03/2018active substances acitretin, adapalene, alitretinoin, bexarotene … active substances acitretin, adapalene, alitretinoin, bexarotene … • For topical retinoids (adapalene, alitretinoin, isotretinoin … -
List item
News: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 4-8 July 2016
PRAC, Last updated: 08/07/2016active substances acitretin, adapalene, alitretinoin, bexarotene … -
List item
Human medicine European public assessment report (EPAR): Targretin
bexarotene, Lymphoma, T-Cell, Cutaneous
Date of authorisation: 29/03/2001, Revision: 23, Authorised, Last updated: 26/01/2022 -
List item
Human medicine European public assessment report (EPAR): Panretin
alitretinoin, Sarcoma, Kaposi
Date of authorisation: 11/10/2000, Revision: 17, Withdrawn, Last updated: 11/01/2021 -
List item
Human medicine European public assessment report (EPAR): Mirvaso
brimonidine tartrate, Skin Diseases
Date of authorisation: 20/02/2014, Revision: 11, Authorised, Last updated: 15/03/2022 -
List item
Referral: Cyproterone- and ethinylestradiol-containing medicines
cyproterone, ethinyl estradiol, associated names: Acnemine, Acneson, Chloe, Clairette, Cyprest, Cyprodiol, Diane 35, Dianette, Feminil, Minerva, Zyrona, Article 107i procedures
Status: European Commission final decision, opinion/position date: 29/05/2013, EC decision date: 25/07/2013, Last updated: 05/08/2013 -
List item
Paediatric Committee (PDCO): 6-9 September 2022
Virtual meeting, from 06/09/2022 to 09/09/2022, Last updated: 26/10/2022 -
List item
PDCO: Agendas, minutes and reports (updated)
Last updated: 08/11/2022 -
List item
PRAC: Agendas, minutes and highlights (updated)
Last updated: 29/11/2022 -
List item
Public data from Article 57 database
Last updated: 17/10/2022 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 7-10 June 2021
European Medicines Agency, Amsterdam, the Netherlands, from 07/06/2021 to 10/06/2021, Last updated: 07/06/2021 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 14-17 May 2018
European Medicines Agency, London, UK, from 14/05/2018 to 17/05/2018, Last updated: 14/05/2018 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 4-7 May 2015
European Medicines Agency, London, UK, from 04/05/2015 to 07/05/2015, Last updated: 13/03/2014 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 5-8 February 2018
European Medicines Agency, London, UK, from 05/02/2018 to 08/02/2018, Last updated: 13/03/2014Retinoids: acitretin (NAP); adapalene (NAP); alitretinoin - PANRETIN … -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 27-30 November 2017
European Medicines Agency, London, UK, from 27/11/2017 to 30/11/2017, Last updated: 27/11/2017Retinoids: acitretin (NAP); adapalene (NAP); alitretinoin - PANRETIN … -
List item
Paediatric Committee (PDCO): 19-22 July 2022
Virtual meeting, from 19/07/2022 to 22/07/2022, Last updated: 24/03/2021 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 4-8 July 2016
European Medicines Agency, London, UK, from 04/07/2016 to 08/07/2016, Last updated: 04/07/2016Retinoids: acitretin (NAP); adapalene (NAP); alitretinoin - PANRETIN … -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 6-9 March 2017
European Medicines Agency, London, UK, from 06/03/2017 to 09/03/2017, Last updated: 06/03/2017Retinoids: acitretin (NAP); adapalene (NAP); alitretinoin - PANRETIN … -
List item
12th pharmacovigilance stakeholder forum
European Medicines Agency, London, UK, 24/09/2018, Last updated: 08/10/2018Finalised Retinoids acitretin, adapalene, alitretinoin, bexarotene … -
List item
Committee for Medicinal Products for Human Use (CHMP): 19-22 March 2018
European Medicines Agency, London, UK, from 19/03/2018 to 22/03/2018, Last updated: 31/05/2018 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 26-29 September 2016
European Medicines Agency, London, UK, from 26/09/2016 to 29/09/2016, Last updated: 13/03/2014Retinoids: acitretin (NAP); adapalene (NAP); alitretinoin - PANRETIN … -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 9-12 January 2017
European Medicines Agency, London, UK, from 09/01/2017 to 12/01/2017, Last updated: 13/03/2014Retinoids: acitretin (NAP); adapalene (NAP); alitretinoin - PANRETIN … -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 2-5 May 2017
European Medicines Agency, London, UK, from 02/05/2017 to 05/05/2017, Last updated: 13/03/2014Retinoids: acitretin (NAP); adapalene (NAP); alitretinoin - PANRETIN …